Tesamorelin is a synthetic peptide analog of growth hormone–releasing hormone (GHRH) designed for research applications involving endocrine signaling, metabolic pathways, and fat metabolism. It functions by stimulating the pituitary gland to increase natural growth hormone (GH) secretion, which in turn elevates insulin-like growth factor 1 (IGF-1) levels. This mechanism makes Tesamorelin a key compound studied in areas such as visceral fat regulation, body composition, and metabolic health.

In research settings, Tesamorelin is commonly investigated for its role in reducing visceral adipose tissue (VAT), improving lipid profiles, and supporting anabolic processes through GH pulsatility rather than direct hormone replacement. Its targeted stimulation allows for a more physiologically aligned GH release pattern compared to exogenous growth hormone.

Tesamorelin is supplied as a lyophilized powder to maintain stability and integrity, requiring proper reconstitution before use in controlled laboratory environments.

Key Research Focus Areas:

• Growth hormone stimulation via GHRH receptor activation

• IGF-1 elevation and downstream anabolic signaling

• Visceral fat reduction and metabolic modulation

• Lipid metabolism and insulin sensitivity pathways

• Endocrine system regulation and peptide signaling